fidas

MAT2A inhibitor 4 is an inhibitor of the catalytic subunit of methionine S-adenosyltransferase-2, which is used in cancer research.

FIDAS-3, a stilbene derivative and potent Wnt inhibitor with an IC50 of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A), exhibits anticancer activities by effectively competing with S-adenosylmethionine (SAM) for MAT2A binding.

FIDAS-5 is an orally active methionine adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM. It can effectively compete with S-adenosylmethionine for MAT2A binding and has anticancer effects.

Fidasimtamab is a recombinant human IgG1 bispecific antibody designed to target and inhibit both HER2 and PD-1 signaling pathways. Fidasimtamab bridges PD-1 expressing T cells with HER2 expressing tumor cells, thereby modulating immune responses while exhibiting potential immunosuppressive and antitumor effects. This mechanism provides an unique therapeutic approach for cancer research.

Ricefidase is an enzyme/recombinant protein related to human IgG and can be used for life science research.